

Bibliography

SCHIZOPHRENIA

This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.

- Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU: Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry* 2011; doi: 10.1038/mp.2011.143 [Epub ahead of print]
- Ventura J, Subotnik KL, Guzik LH, Helleman GS, Gitlin MJ, Wood RC, Nuechterlein KH: Remission and recovery during the first outpatient year of the early course of schizophrenia. *Schizophr Res* 2011; 132:18–23
- Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Gejman PV, et al.: Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium: Genome-wide association study identifies five new schizophrenia loci. *Nat Genet* 2011; 43:969–976
- Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM. Translating glutamate: from pathophysiology to treatment. *Sci Transl Med.* 2011 Sep 28;3(102):102mr2.
- Lieberman JA, Stroup TS: The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry 2011; 168:770–775**
- Belgamwar RB, El-Sayeh HG: Aripiprazole versus placebo for schizophrenia. *Cochrane Database Syst Rev* 2011; (8): CD006622
- Daumit GL, Dalcin AT, Jerome GJ, Young DR, Charleston J, Crum RM, Anthony C, Hayes JH, McCarron PB, Khaykin E, Appel LJ: A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers. *Int J Obes (Lond)* 2011; 35:1114–1123
- McFarland BH, Collins JC: Medicaid cutbacks and state psychiatric hospitalization of patients with schizophrenia. Psychiatr Serv 2011; 62:871–877**
- Foley DL, Morley KI: Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. *Arch Gen Psychiatry* 2011; 68:609–616
- Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. *Am J Psychiatry* 2011; 168:472–485
- Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S: Oral versus depot antipsychotic drugs for schizophrenia—a critical systematic review and meta-analysis of randomised long-term trials. *Schizophr Res* 2011; 127:83–92
- Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Helleman GS, Thornton LA, Singh IR: Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168:286–292**
- Strom BL, Eng SM, Faich G, Reynolds RF, D’Agostino RB, Ruskin J, Kane JM: Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). *Am J Psychiatry* 2011; 168:193–201
- Tranulis C, Goff D, Henderson DC, Freudenreich O: Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. *Psychiatr Serv* 2011; 62:888–892
- Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R: Are we addressing the ‘right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. *Schizophr Res* 2011; 132:42–49
- Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH; CSP555 Research Group: Long-acting risperidone and oral antipsychotics in unstable schizophrenia. *N Engl J Med* 2011; 364:842–851
- Farooq S, Nazar Z, Irfan M, Akhter J, Gul E, Irfan U, Naeem F: Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). *Br J Psychiatry* 2011; 199:467–472
- Green MF, Schooler NR, Kern RS, et al: Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. *Am J Psychiatry* 2011; 168:400–407
- Dickerson FB, Lehman AF: Evidence-based psychotherapy for schizophrenia: 2011 update. J Nerv Ment Dis 2011; 199:520–526**
- Insel TR: Rethinking schizophrenia. *Nature* 2010; 468:187–193
- Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2010; 123:225–233

- Ballon JS, Lieberman JA: Advances in the management of treatment-resistant schizophrenia. *Focus* 2010; 8:475–487
- Foti DJ, Kotov R, Guey LT, Bromet EJ: Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. *Am J Psychiatry* 2010; 167:987–993
- Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. *Am J Psychiatry* 2010; 167:261–280
- Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. *Am J Psychiatry* 2010; 167:181–189
- Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. *Arch Gen Psychiatry* 2010; 67:146–154
- Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. *Schizophr Bull* 2010; 36:48–70
- Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT): The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. *Schizophr Bull* 2010; 36:94–103
- Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himmelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull* 2010; 36:71–93**
- Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, Liu TQ, Wang GH, Weng SM, Zhang HY, Chen DF, Tang WK, Ungvari GS: Risperidone Maintenance Treatment in Schizophrenia (RMTS) investigators: Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. *Am J Psychiatry* 2010; 167:676–685
- Remington G, Foussias G, Agid O: Progress in defining optimal treatment outcome in schizophrenia. *CNS Drugs* 2010; 24:9–20
- Hill M, Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Kinsella A, Waddington JL, Larkin C, O'Callaghan E: Nonadherence to medication four years after a first episode of psychosis and associated risk factors. *Psychiatr Serv* 2010; 61:189–192
- Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, Rössler W, Fleischhacker WW; EUFEST Study Group: Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). *Eur Neuropsychopharmacol* 2010; 20:310–316
- Velligan D, Sajatovic M, Valenstein M, Riley WT, Safren S, Lewis-Fernandez R, Weiden P, Ogedegbe G, Jamison J: Methodological challenges in psychiatric treatment adherence research. *Clin Schizophr Relat Psychoses* 2010; 4:74–91
- Tiihonen J, Lönqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). *Lancet* 2009; 374:620–627
- Leucht S, Kissling W, Davis JM: Second-generation antipsychotics for schizophrenia: can we resolve the conflict? *Psychol Med* 2009; 39:1591–1602
- Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, Kasperaviciute D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayatilake K, Cola PA, McEvoy JP, Keefe RS, Fisher EM, St Jean PL, Giegling I, Hartmann AM, Möller HJ, Ruppert A, Fraser G, Crombie C, Middleton LT, St Clair D, Roses AD, Muglia P, Francks C, Rujescu D, Meltzer HY, Goldstein DB: A genome-wide investigation of SNPs and CNVs in schizophrenia. *PLoS Genet* 2009; 5:e1000373 [open access] doi:10.1371/journal.pgen.1000373
- Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry* 2009; 166:152–163
- Staring AB, Mulder CL, Duivenvoorden HJ, De Haan L, Van der Gaag M: Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life. *Schizophr Res* 2009; 113:27–33
- Kern RS, Glynn SM, Horan WP, Marder SR: Psychosocial treatments to promote functional recovery in schizophrenia. *Schizophr Bull* 2009; 35:347–361
- Kraemer HC, Glick ID, Klein DF: Clinical trials design lessons from the CATIE study. *Am J Psychiatry* 2009; 166:1222–1228
- Buckley PF, Foster A, Miller B: Schizophrenia host vulnerability and risk of metabolic disturbances during treatment with antipsychotics. *Focus* 2008; 6:172–179
- Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V, Grasset F, Borgeat F, Zullino D: Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. *Schizophr Res* 2007; 91:169–177
- Velligan DI, Diamond PM, Mintz J, Maples N, Li X, Zeber J, Ereshefsky L, Lam YW, Castillo D, Miller AL: The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. *Schizophr Bull* 2008; 34:483–493

- Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. *J Clin Psychiatry* 2007; 68:1751–1762
- Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? *Arch Gen Psychiatry* 2007; 64:1123–1131
- Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *Lancet* 2007; 370:319–328
- Pompili M, Amador XF, Girardi P, Harkavy-Friedman J, Harrow M, Kaplan K, Krausz M, Lester D, Meltzer HY, Modestin J, Montross LP, Mortensen PB, Munk-Jørgensen P, Nielsen J, Nordentoft M, Saarinen PI, Zisook S, Wilson ST, Tatarelli R: Suicide risk in schizophrenia: learning from the past to change the future. *Ann Gen Psychiatry* 2007; 6:10
- Miller BJ, Paschall CB 3rd, Svendsen DP: Mortality and medical comorbidity among patients with serious mental illness. *Psychiatr Serv* 2006; 57:1482–1487
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; 353:1209–1223
- McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophr Res* 2005; 80:19–32
- Meltzer HY, Alphas L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S; International Suicide Prevention Trial Study Group: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry* 2003; 60:82–91

NOTES